BioInvent International AB (publ)
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Martin Welschof
- Full Time Employees
- 114
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- The Gamma Building Lund Sweden 223 70
- IPO Date
- Sep 3, 2013
- Website
- bioinvent.com
- Similar Companies
- Business
- BioInvent International AB (publ) is a clinical-stage biotechnology firm dedicated to discovering and advancing innovative immuno-modulatory antibodies to combat cancer. The company leverages its proprietary F.I.R.S.T™ technology platform and n-CoDeR® antibody library to identify novel targets and generate first-in-class drug candidates. Its pipeline includes lead candidates such as BI-1206, an anti-FcγRIIB antibody, currently being evaluated in Phase 2a trials for non-Hodgkin lymphoma in a triple combination with rituximab and Calquence®, and also initiating Phase 2a studies for advanced or metastatic non-small cell lung cancer (NSCLC) and uveal melanoma. Another key asset, BI-1808, an anti-TNFR2 antibody, is progressing through Phase 1/2a studies for solid tumors and cutaneous T-cell lymphoma (CTCL), having recently received Orphan Drug Designation from both the FDA and EMA for T-cell lymphoma and CTCL respectively. While strategically prioritizing its most advanced programs, BioInvent continues to report on other assets. Phase 1 clinical data for BI-1910, a TNFR2 Agonist targeting solid tumors, was presented at SITC 2025. Additionally, BT-001, an oncolytic virus co-developed with Transgene, is being advanced through investigator-led trials for solid tumors. Preclinical and early Phase 1 data for BI-1607, an anti-FcγRIIB antibody, in HER2-positive advanced solid tumors was published, and it is also undergoing a Phase 1b/2a study in combination with other agents for metastatic melanoma. BioInvent generates revenue through research collaborations and licensing agreements with leading pharmaceutical entities, alongside its integrated manufacturing unit that produces antibodies for both internal development and third-party clients across Europe, the United States, Japan, and Australia. The company, established in 1996, operates from its headquarters in Lund, Sweden.
BioInvent International AB (publ) (BOVNF) Discusses Ovarian Cancer Treatment Landscape and TNFR2-Targeted Therapies in Solid Tumors Transcript
BioInvent to Host Virtual KOL Event to Discuss BI-1808 for the Treatment of Ovarian Cancer, on May 27, 2026
Resolutions at BioInvent's Annual General Meeting 2026
BioInvent to Host Two Key Opinion Leader Events Highlighting Progress Across Oncology Portfolio
BioInvent International AB: Interim Report January - March 2026
BioInvent to Present Data of BI-1808 Plus KEYTRUDA(R) (Pembrolizumab) in Recurrent Ovarian Cancer at the 2026 ASCO Annual Meeting
BioInvent International AB Publishes Annual Report 2025
Notice to Annual General Meeting in BioInvent International AB
BioInvent International AB (publ) (BOVNF) Q4 2025 Earnings Call Transcript
BioInvent International AB: Year-End Report January 1 - December 31, 2025